Breast cancer: new treatments in sight
22 June 2016
In a new study, biologists from the University of Geneva reveal why patients develop a resistance to the most frequently used therapies against breast cancer. Estrogens are responsible for the survival and proliferation of tumor cells in about three-fourths of all breast cancer cases. The most frequently used treatments against breast cancer therefore rely on […]
In a new study, biologists from the University of Geneva reveal why patients develop a resistance to the most frequently used therapies against breast cancer.
Estrogens are responsible for the survival and proliferation of tumor cells in about three-fourths of all breast cancer cases. The most frequently used treatments against breast cancer therefore rely on anti-estrogens such as tamoxifen, which block malignant cell growth by inhibiting the activity of certain estrogen receptors. However, nearly one in three women develop a resistance to these hormonal treatments after a few years. In a discovery that could pave the way for new therapies, researchers from the University of Geneva (UNIGE) have identified eight factors involved in the process of resistance to the treatment. The study was published in the journal Nucleic Acids Research.
Didier Picard, professor at the Department of Cell Biology of the Faculty of Sciences of UNIGE, and his team discovered that several enzymes come into play to allow a particular estrogen receptor – the motor of cancerous growth – to access the genes necessary for cell growth. Diverse protein complexes and cofactors also play a role. The discovery of a range of factors with unexpected functions prompted the researchers to test them as potential therapeutic targets, according to a press release. The biologists tested various compounds in vitro on mammary cancer cells having become refractory to tamoxifen, and found that the inhibitors of the factors discovered during the study hamper the proliferation of cancer cells and restore tamoxifen sensitivity to the malignant cells.